Exelixis slides 12% on Q2 misses, pipeline update

12 hours ago 1

Exelixis (NASDAQ:EXEL) is down ~12% in after-hours trading Monday after posting Q2 financial results that missed on both lines.
The company is maintaining its financial guidance for 2025.
The biotech also said that it will not move candidate zanzalintinib into phase

Recommended For You